Incyte Corporation - Common Stock (NQ:INCY)

115.30 -1.84 (-1.57%)

Delayed Quote Updated: 4:00 PM EDT, Oct 2, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Incyte Corporation - Common Stock

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

29 30 Next >

Q1 Immuno-Oncology Earnings Review: First Prize Goes to Natera (NASDAQ:NTRA)

June 29, 2025

Let’s dig into the relative performance of Natera (NASDAQ:NTRA) and its peers as we unravel the now-completed Q1 immuno-oncology earnings season.

Via StockStory

Topics Artificial Intelligence

Top S&P500 movers in Friday's session ↗

June 27, 2025

Uncover the latest developments among S&P500 stocks in today's session. Stay tuned to the S&P500 index's top gainers and losers on Friday.

Via Chartmill

Incyte CEO Shake-Up Sparks M&A Buzz As RBC Analyst Highlights Meury’s Track Record: Retail Is All In ↗

June 27, 2025

Bill Meury previously led Karuna Therapeutics through a $14 billion sale to Bristol Myers Squibb and steered Anthos Therapeutics ahead of its acquisition by Novartis.

Via Stocktwits

Topics Intellectual Property

Uncover the latest developments among S&P500 stocks in today's session. ↗

June 26, 2025

Stay updated with the movements of the S&P500 index one hour before the close of the markets on Thursday. Discover which stocks are leading as top gainers and losers in today's session.

Via Chartmill

Where Incyte Stands With Analysts ↗

June 03, 2025

Via Benzinga

Thursday's session: top gainers and losers in the S&P500 index ↗

June 26, 2025

Join us in exploring the top gainers and losers within the S&P500 index in the middle of the day on Thursday as we examine the latest happenings in today's session.

Via Chartmill

Why New Incyte CEO Bill Meury Is Stoking Investors' M&A Hopes ↗

June 26, 2025

Bill Meury will take the place of Herve Hoppenot, who is retiring after 11 years at Incyte's helm.

Via Investor's Business Daily

Get insights into the top movers in the S&P500 index of Thursday's pre-market session. ↗

June 26, 2025

Curious about the S&P500 stocks that are showing activity before the opening bell on Thursday?

Via Chartmill

Incyte Appoints Bill Meury Chief Executive Officer; Hervé Hoppenot to Retire

June 26, 2025

From Incyte

Via Business Wire

Update on FDA Review of Ruxolitinib Cream (Opzelura®) for Children Ages 2-11 with Atopic Dermatitis

June 20, 2025

From Incyte

Via Business Wire

INCYTE CORP (NASDAQ:INCY) – A Biopharmaceutical Stock with Undervalued Potential ↗

June 20, 2025

INCYTE CORP (NASDAQ:INCY) shows strong valuation, profitability, and financial health, making it an interesting pick for value investors. The stock trades at a discount to peers with solid growth...

Via Chartmill

3 Low-Volatility Stocks with Questionable Fundamentals

June 20, 2025

Stability is great, but low-volatility stocks may struggle to deliver market-beating returns over time as they sometimes underperform during bull markets.

Via StockStory

Incyte Announces FDA Approval of Monjuvi® (tafasitamab-cxix) in Combination with Rituximab and Lenalidomide for Patients with Relapsed or Refractory Follicular Lymphoma

June 18, 2025

From Incyte

Via Business Wire

3 Unpopular Stocks in Hot Water

June 17, 2025

Wall Street’s bearish price targets for the stocks in this article signal serious concerns. Such forecasts are uncommon in an industry where maintaining cordial corporate relationships often trumps...

Via StockStory

Stay updated with the S&P500 stocks that are on the move in today's pre-market session. ↗

June 16, 2025

Curious about the S&P500 stocks that are showing activity before the opening bell on Monday?

Via Chartmill

Incyte's Experimental Therapy Shows Platelet Normalization And Safety In Rare Blood Cancer Trials Across Doses ↗

June 16, 2025

Incyte's INCA033989 showed early efficacy and strong tolerability in essential thrombocythemia patients with mutCALR, supporting further development.

Via Benzinga

Why Incyte Shares Are Trading Higher By Around 10%; Here Are 20 Stocks Moving Premarket ↗

June 16, 2025

Via Benzinga

Retail Investors Flock To Incyte As Drug Data, Qiagen Deal Fuel Optimism ↗

June 16, 2025

Stifel also upgraded the stock to ‘Buy’ with a $107 price target.

Via Stocktwits

QIAGEN and Incyte Announce Precision Medicine Collaboration to Develop Companion Diagnostics for Patients With Mutant CALR-expressing Myeloproliferative Neoplasms (MPNs)

June 15, 2025

From QIAGEN N.V.

Via Business Wire

Positive Late-Breaking Data for Incyte’s First-in-Class mutCALR-targeted therapy INCA033989 in Essential Thrombocythemia Presented at EHA2025

June 15, 2025

From Incyte

Via Business Wire

Phase 3 Data for Incyte’s Retifanlimab (Zynyz®) in Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC) Published in The Lancet

June 12, 2025

From Incyte

Via Business Wire

Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

June 06, 2025

From Incyte

Via Business Wire

Incyte Announces Multiple Presentations, Including New Late-Breaking Data for its mutCALR-Directed Monoclonal Antibody (INCA033989), Accepted for Presentation at EHA 2025

June 03, 2025

From Incyte

Via Business Wire

INCYTE CORP (NASDAQ:INCY) – A Potential Undervalued Opportunity in Biotech ↗

May 30, 2025

INCYTE CORP (NASDAQ:INCY) presents a compelling value case with strong profitability, low debt, and an attractive valuation. The biotech firm's fundamentals suggest potential upside for long-term...

Via Chartmill

Incyte to Present at Upcoming Investor Conference

May 27, 2025

From Incyte

Via Business Wire

What's going on in today's session: S&P500 movers ↗

May 20, 2025

Stay informed about the performance of the S&P500 index one hour before the close of the markets on Tuesday. Uncover the top gainers and losers in today's session for valuable insights.

Via Chartmill

3 Mid-Cap Stocks with Questionable Fundamentals

May 20, 2025

Mid-cap stocks have the best odds of scaling into $100 billion corporations thanks to their tested business models and large addressable markets. But the many opportunities in front of them attract...

Via StockStory

Incyte Announces FDA Approval of Zynyz® (retifanlimab-dlwr) Making it the First and Only Approved First-Line Treatment for Advanced Anal Cancer Patients in the United States

May 15, 2025

From Incyte

Via Business Wire

INCY Q1 Earnings Call: New Product Launches and Pipeline Progress Drive Outperformance

May 13, 2025

Biopharmaceutical company Incyte Corporation (NASDAQ:INCY) reported Q1 CY2025 results exceeding the market’s revenue expectations, with sales up 19.5% year on year to $1.05 billion. Its non-GAAP profit...

Via StockStory

Topics World Trade

These S&P500 stocks that are showing activity before the opening bell on Thursday. ↗

May 08, 2025

Curious about the S&P500 stocks that are showing activity before the opening bell on Thursday?

Via Chartmill

< Previous 1 2

...

6 7 8 9 10 11 12 13 14

...

29 30 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.